State of New Jersey Common Pension Fund D Increases Stock Holdings in Xenon Pharmaceuticals Inc. $XENE

State of New Jersey Common Pension Fund D lifted its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 22.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 61,772 shares of the biopharmaceutical company’s stock after buying an additional 11,355 shares during the period. State of New Jersey Common Pension Fund D owned about 0.08% of Xenon Pharmaceuticals worth $1,933,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Xenon Pharmaceuticals by 15.7% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,964 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 403 shares during the last quarter. Mutual of America Capital Management LLC purchased a new position in shares of Xenon Pharmaceuticals during the first quarter valued at approximately $1,636,000. Natixis Advisors LLC boosted its position in shares of Xenon Pharmaceuticals by 1.9% during the first quarter. Natixis Advisors LLC now owns 24,010 shares of the biopharmaceutical company’s stock valued at $806,000 after buying an additional 456 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Xenon Pharmaceuticals by 439.0% during the first quarter. Bank of New York Mellon Corp now owns 251,147 shares of the biopharmaceutical company’s stock valued at $8,426,000 after buying an additional 204,550 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ boosted its position in shares of Xenon Pharmaceuticals by 17.5% during the first quarter. Skandinaviska Enskilda Banken AB publ now owns 47,457 shares of the biopharmaceutical company’s stock valued at $1,592,000 after buying an additional 7,081 shares during the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Stock Down 1.8%

XENE stock opened at $41.92 on Friday. The firm has a market capitalization of $3.23 billion, a PE ratio of -11.81 and a beta of 1.14. Xenon Pharmaceuticals Inc. has a twelve month low of $26.74 and a twelve month high of $46.00. The stock has a 50-day simple moving average of $39.34 and a two-hundred day simple moving average of $35.31.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its earnings results on Monday, August 11th. The biopharmaceutical company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.04). During the same quarter last year, the firm earned ($0.75) earnings per share. On average, equities research analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on XENE shares. Bloom Burton raised Xenon Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, October 7th. William Blair reaffirmed an “outperform” rating on shares of Xenon Pharmaceuticals in a research report on Tuesday, October 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Tuesday, October 14th. Chardan Capital reissued a “buy” rating and issued a $55.00 price objective on shares of Xenon Pharmaceuticals in a research report on Tuesday, October 7th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, September 2nd. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $53.67.

Insiders Place Their Bets

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 25,000 shares of Xenon Pharmaceuticals stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $40.16, for a total transaction of $1,004,000.00. Following the completion of the transaction, the chief executive officer owned 31,302 shares of the company’s stock, valued at $1,257,088.32. The trade was a 44.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.07% of the stock is owned by insiders.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.